16 March 2010 Corporate Presentation Q1 2010 01 March 2010 Progen Appoints Additional Company Secretary 26 February 2010 Appendix 4D - Interim Financial Report 01 December 2009 Progen Appoints Dr. John Chiplin as Interim CEO 01 December 2009 Results of Annual General Meeting 30 November 2009 26 November 2009 Director Resignations 24 November 2009 Notice of Initial Substantial Holder 18 November 2009 Legal Update - Settlement Reached 9 November 2009 Legal Update 22 October 2009 Legal Update 14 October 2009 New Preclinical Data confirms PG545 as a promising clinical candidate for cancer 15 September 2009 Legal Update 09 September 2009 Progen's PG11047 Phase 1 Study Completed 04 August 2009 Progen Issues Proceedings 03 August 2009 Appendix 3X Revised - Joe Yeh-Chiao Lin 29 July 2009 Summary of Director Credentials 27 July 2009 Appendix 3X 27 July 2009 Appendix 3X 27 July 2009 Appendix 3X 21 July 2009 Chairman's Address to Shareholders - General Meeting 17 July 2009 Results of General Meeting 17 July 2009 17 July 2009 Appendix 3X - Gordon Schooley 09 July 09 Appendix 3Z 09 July 09 Appendix 3Z 09 July 09 Appendix 3Z 08 July 2009 Appendix 3X 08 July 2009 Appendix 3X 08 July 2009 Appendix 3X 08 July 2009 Appendix 3X 07 July 2009 Letter to Shareholders: Our New Board 03 July 2009 Progen Receives NASDAQ Listing Rules Clearance on Board Structure Deficiency 01 July 2009 Progen Board Restructure Provides Strength and Experience 01 July 2009 Progen Board Restructure - Summary of Director Credentials 30 June 2009 Progen's Pharmasynth Secures Global Muparfostat License 10 June 2009 Notice of General Meeting 18 May 2009 Progen Commences Negotiations for Global Licensing of PI-88 01 May 2009 Appendix 3Y 27 April 2009 Appendix 3F 27 April 2009 Results of Equal Access Buy-Back Scheme 22 April 2009 Progen Receives NASDAQ Notice Regarding Board Composition 22 April 2009 Results of General Meeting 22 April 2009 21 April 2009 Update on Director Intentions Regarding Off-Market Share Buy-Back 20 April 2009 AACR 2009 Announcement 31 March 2009 Appendix 3X 31 March 2009 Appendix 3Z 31 March 2009 Appendix 3Z 31 March 2009 Appendix 3Z 31 March 2009 Appendix 3Z 27 March 2009 Progen Appoints Nonexecutive Director 27 March 2009 Results of Shareholder Meeting 27 March 2009 23 March 2009 $40m Share Buyback Notice of Meeting and Buyback Booklet 17 March 2009 Cytopia Letter Confuses on Buy Back and Proposed Merger 17 March 2009 Letter to Shareholders: Important Update 10 March 2009 Progen $40m (60%) Share Buyback at $1.10 09 March 2009 Progen withdraws from Avexa Merger announces $40m Buyback 05 March 2009 Cytopia commences court proceedings to prevent the 11 March meeting 02 March 2009 Shareholders urged to REJECT Cytopia's call to adjourn Merger Meeting 02 March 2009 Share Buyback Booklet - Avexa Merger Transaction 19 February 2009 Financial Report for the half-year ended 31 December 2008 19 February 2009 Progen Half Year Financial Results 18 February 2009 Requisitioned General Meeting 27 March 2009 Announcement 18 February 2009 Notice of Requisitioned General Meeting 27 March 2009 11 February 2009 Avexa and Progen Shareholder Forums to be held the week commencing the 23 of February 2009 5 February 2009 Progen Reaction to Requisition for General Meeting 5 February 2009 Progen- Avexa Merger Notice of Meeting and Independent Expert Report 5 February 2009 Chairmans Letter to Shareholders: Progen-Avexa Merger 5 February 2009 Notice of Meeting Documentation: Progen-Avexa Merger 5 February 2009 Appendix 3C 28 January 2009 Response to Requisitioned General Meeting 23 January 2009 Progen-Avexa Merger Update 13 January 2009
2008 Form 20-F Filed with US SEC 9 January 2009 Shareholder Support for Progen Board 9 January 2009 Results of Requisitioned General Meeting 6 January 2009 Avexa and Progen Merger Investor Forum Presentation